203 related articles for article (PubMed ID: 29386247)
1. The role of the AR/ER ratio in ER-positive breast cancer patients.
Rangel N; Rondon-Lagos M; Annaratone L; Osella-Abate S; Metovic J; Mano MP; Bertero L; Cassoni P; Sapino A; Castellano I
Endocr Relat Cancer; 2018 Mar; 25(3):163-172. PubMed ID: 29386247
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma.
Wijesinghe HD; Wijesinghe GK; Mansoor Z; Vigneshwara S; Fernando J; Gunasekera D; Lokuhetty MDS
BMC Womens Health; 2020 Sep; 20(1):206. PubMed ID: 32928183
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
[TBL] [Abstract][Full Text] [Related]
5. AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors.
Rangel N; Rondon-Lagos M; Annaratone L; Aristizábal-Pachon AF; Cassoni P; Sapino A; Castellano I
Cells; 2020 Apr; 9(4):. PubMed ID: 32344660
[TBL] [Abstract][Full Text] [Related]
6. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
7. Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer.
Tokunaga E; Hisamatsu Y; Taketani K; Yamashita N; Akiyoshi S; Okada S; Tanaka K; Saeki H; Oki E; Aishima S; Oda Y; Morita M; Maehara Y
Cancer Med; 2013 Dec; 2(6):763-73. PubMed ID: 24403250
[TBL] [Abstract][Full Text] [Related]
8. Expression of Androgen Receptor in Estrogen Receptor-positive Breast Cancer.
Agrawal A; Ziolkowski P; Grzebieniak Z; Jelen M; Bobinski P; Agrawal S
Appl Immunohistochem Mol Morphol; 2016 Sep; 24(8):550-5. PubMed ID: 26230371
[TBL] [Abstract][Full Text] [Related]
9. FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients.
Rangel N; Fortunati N; Osella-Abate S; Annaratone L; Isella C; Catalano MG; Rinella L; Metovic J; Boldorini R; Balmativola D; Ferrando P; Marano F; Cassoni P; Sapino A; Castellano I
BMC Cancer; 2018 Jul; 18(1):703. PubMed ID: 29970021
[TBL] [Abstract][Full Text] [Related]
10. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters.
Kuenen-Boumeester V; Van der Kwast TH; Claassen CC; Look MP; Liem GS; Klijn JG; Henzen-Logmans SC
Eur J Cancer; 1996 Aug; 32A(9):1560-5. PubMed ID: 8911118
[TBL] [Abstract][Full Text] [Related]
12. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.
Ethier JL; Ocaña A; Rodríguez Lescure A; Ruíz A; Alba E; Calvo L; Ruíz-Borrego M; Santaballa A; Rodríguez CA; Crespo C; Ramos M; Gracia Marco J; Lluch A; Álvarez I; Casas M; Sánchez-Aragó M; Carrasco E; Caballero R; Amir E; Martin M
Eur J Cancer; 2018 May; 94():199-205. PubMed ID: 29573665
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
Bronte G; Rocca A; Ravaioli S; Puccetti M; Tumedei MM; Scarpi E; Andreis D; Maltoni R; Sarti S; Cecconetto L; Fedeli A; Pietri E; De Simone V; Asioli S; Amadori D; Bravaccini S
BMC Cancer; 2018 Mar; 18(1):348. PubMed ID: 29587674
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
[TBL] [Abstract][Full Text] [Related]
16. Impact of Androgen Receptor Expression and the AR:ER Ratio on the Survival Outcomes in the Diverse Subgroups of Vietnamese Breast Cancer: A Single Institutional Retrospective Cohort Analysis.
Phung HT; Nguyen CV; Mai NT; Vu HTN; Pham KH; Tran GL
Technol Cancer Res Treat; 2022; 21():15330338221080941. PubMed ID: 35379053
[No Abstract] [Full Text] [Related]
17. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
[TBL] [Abstract][Full Text] [Related]
18. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up.
Bustreo S; Osella-Abate S; Cassoni P; Donadio M; Airoldi M; Pedani F; Papotti M; Sapino A; Castellano I
Breast Cancer Res Treat; 2016 Jun; 157(2):363-371. PubMed ID: 27155668
[TBL] [Abstract][Full Text] [Related]
19. Lin28A and androgen receptor expression in ER-/Her2+ breast cancer.
Shen H; Yang Y; Zhao L; Yuan J; Niu Y
Breast Cancer Res Treat; 2016 Feb; 156(1):135-47. PubMed ID: 26944953
[TBL] [Abstract][Full Text] [Related]
20. Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis.
Lu C; Yang Y; Lingmei L; Qiujuan H; Qianru G; Lisha Q; Wenfeng C; Yun N; Peisen Z
Breast Cancer Res Treat; 2023 Jan; 197(1):71-82. PubMed ID: 36334189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
